About Candel

The cancer treatment paradigm has shifted dramatically over the last decade, providing evidence that the immune system can be reactivated against a patient’s tumor. The mechanism of action of oncolytic viral immunotherapies is unique in combining both an anti-tumor cytotoxic component and an immune-stimulatory component. Together, these modalities lead to an “in-situ vaccination” effect against the tumor.

At Candel Therapeutics, we are developing immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications.


Candel’s products are designed to improve survival while maintaining quality of life – from early- to late-stage disease.

Our MISSION

to save, extend and improve the lives of patients through oncolytic viral immunotherapies.


Our PLAN

to harness the power of our proprietary virus-based approaches and elicit a broad, potent immune response against solid tumors and their metastases.

OUR LEADERSHIP

is made up of renowned drug developers, oncolytic viral immunotherapy experts, oncologists, immunologists and biotech business leaders. Candel is built on science, and our experienced team is helping translate its full promise to patients.

RESEARCH ADVISORY BOARD

SCIENTIFIC ADVISORS

© 2021 by Candel Therapeutics